8-K: NovaBay Board Deems Refresh Acquisition Offer Superior, Plans to Terminate PRN Deal Unless Counteroffer Received

NovaBay Pharmaceuticals has determined an unsolicited offer from Refresh Acquisitions to purchase its Avenova assets is superior to its existing agreement with PRN, potentially leading to a termination of the PRN deal.

Summary

• NovaBay Pharmaceuticals has received an unsolicited, non-binding acquisition proposal from Refresh Acquisitions BidCo LLC to purchase the Avenova brand and related assets.
• The NovaBay Board of Directors has determined that the Refresh offer is a Superior Proposal compared to the existing Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC.
• The Refresh offer includes a base purchase price of $11.5 million, which is $2 million higher than the $9.5 million offered by PRN, subject to a net working capital adjustment.
• Refresh is also offering a $2.0 million secured term loan to NovaBay with a 10.0% annual interest rate, which will be repaid upon closing of the transaction and deducted from the purchase price.
• NovaBay has notified PRN of its intention to terminate the PRN agreement unless PRN submits a revised proposal by November 4, 2024, that makes the Refresh offer no longer superior.
• The PRN agreement remains in effect, and the Board has not withdrawn its recommendation for the PRN transaction, pending PRN's response.
• The company is also considering a potential voluntary liquidation and dissolution.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the higher offer from Refresh is positive, the potential termination of the PRN deal and the secured loan at 10% interest introduce uncertainty. The consideration of a potential voluntary liquidation and dissolution also adds a negative element.

Positives

• The Refresh offer provides a higher purchase price of $11.5 million compared to the $9.5 million offered by PRN.
• The $2.0 million secured term loan from Refresh could provide immediate financial support to NovaBay.
• The potential acquisition by Refresh could place Avenova in the hands of a company with a complementary product, Upneeq, potentially enhancing its market reach.
• The board conducted a comprehensive evaluation of the Refresh offer with assistance from independent financial and legal advisors.

Negatives

• The potential termination of the PRN agreement introduces uncertainty and could lead to additional costs.
• The secured loan from Refresh comes with a 10.0% annual interest rate, which could be a financial burden.
• The Refresh offer is subject to a net working capital adjustment, which could reduce the final purchase price.
• The company is also considering a potential voluntary liquidation and dissolution.

Risks

• There is a risk that PRN may not submit a counteroffer, leading to the termination of the PRN agreement.
• The Refresh offer is non-binding and could be withdrawn.
• The net working capital adjustment in the Refresh offer could reduce the final purchase price.
• The company is also considering a potential voluntary liquidation and dissolution.
• The company is subject to risks and uncertainties that could cause actual results to differ materially from those projected in forward-looking statements.

Future Outlook

The company is awaiting a response from PRN by November 4, 2024, to determine whether the PRN agreement will be terminated in favor of the Refresh offer. The company is also considering a potential voluntary liquidation and dissolution.

Management Comments

• Justin Hall, NovaBay CEO, stated that the Refresh offer represents greater value for stockholders and places Avenova in capable commercial hands.
• Justin Hall also noted the alignment between RVL Pharmaceuticals and NovaBay in their shared passion for commercializing products that improve patients' lives.

Industry Context

The potential acquisition of Avenova by Refresh, an affiliate of RVL Pharmaceuticals, aligns with a trend of consolidation in the eyecare market. RVL's Upneeq product is complementary to Avenova, suggesting a strategic move to offer a more comprehensive suite of eyecare solutions.

Comparison to Industry Standards

• The acquisition of Avenova by Refresh is similar to other acquisitions in the pharmaceutical and healthcare space where companies seek to expand their product portfolios and market reach.
• The $11.5 million purchase price, while subject to adjustments, is a typical valuation for a brand like Avenova, which has established market presence in the eyecare sector.
• The secured loan at 10% interest is a common financing method in such transactions, although the rate is relatively high, reflecting the risk associated with the company's current financial situation.
• Comparable companies in the eyecare space include those focused on dry eye treatments and eyelid hygiene, such as companies that produce similar products to Avenova.

Stakeholder Impact

• Shareholders may benefit from the higher purchase price offered by Refresh.
• Employees may face uncertainty due to the potential change in ownership and the possibility of a company dissolution.
• Customers may experience changes in product availability and distribution channels.
• Suppliers may need to adjust to new business relationships.
• Creditors may be impacted by the potential liquidation and dissolution.

Next Steps

• PRN has until November 4, 2024, to submit a revised proposal.
• The NovaBay Board will evaluate any counteroffer from PRN.
• If no counteroffer is received, the company will proceed with the Refresh offer.
• The company will continue to seek stockholder approval for the PRN transaction and potential dissolution.

Key Dates

Keywords

Avenova, acquisition, Refresh Acquisitions, PRN Physician Recommended Nutriceuticals, asset purchase agreement, superior proposal, secured loan, eyecare, liquidation, dissolution